Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? MS ID#: NEURIMMINFL/ 2018/019398

Published: 21 June 2020| Version 1 | DOI: 10.17632/ht5s9cc845.1
Hadas Stiebel-Kalish


In this study we tested the hypothesis that timing of intravenous (IVMP) affects visual outcome in a cohort of aquaporin4 (AQP4)-IgG and MOG-IgG positive patients with ON by analyzing the effect of the number of days until treatment commenced with the best-corrected visual acuity at three months. The results provides Class III evidence that hyperacute treatment of AQP4 and MOG-ON with IVMP increases the chance for excellent visual recovery (20/20 vision) and that even a greater than 7 day delay in treatment is associated with a higher risk for poor visual recovery.